Orodispersible film (ODF) is the pharmacopoeial term: a single- or multilayer sheet that disperses rapidly in the mouth. Sublingual and buccal describe where a film is placed, not how much is absorbed. Oral thin film (OTF), fast-dissolving strip and melt-in-mouth strip are trade and search terms with no measurable content. Write the specification in ODF terms and keep placement words off the front panel unless you have data behind them.
| Term | Where it comes from | What it specifies | What it does not specify | Marketed example |
|---|---|---|---|---|
| Orodispersible film (ODF) | Ph. Eur. monograph 1807, Oromucosal preparations | A single- or multilayer sheet placed in the mouth where it disperses rapidly | Absorption site, exact seconds, regulatory class | Ondansetron oral soluble film: placed on the tongue, dissolves in 4–20 s, then swallowed |
| Oral film / film, soluble | FDA SPL dosage-form vocabulary (FILM; FILM, SOLUBLE; FILM, EXTENDED RELEASE) | A drug-listing dosage form | Route; supplement strips never use it | Clobazam oral film: applied on top of the tongue, adheres and dissolves |
| Sublingual film | Route of administration, not a dosage form | Placement under the tongue | Rate or extent of absorption | Buprenorphine/naloxone sublingual film: held in place until dissolved, 5–10 min; also labelled for buccal placement |
| Buccal film | Route; Ph. Eur. mucoadhesive buccal films | Adhesion to the cheek lining and residence time | Dose (the marketed example runs 75–900 mcg) | Buprenorphine buccal film: adheres to the cheek, dissolves in about 30 min |
| OTF, fast-dissolving strip, melt-in-mouth strip | Trade and search vocabulary | Nothing measurable | Everything | Breath strips (pullulan, menthol, flavor) sold as oral care; supplement strips on marketplaces |
| Orally disintegrating tablet (ODT), for contrast | FDA guidance, 2008 | Disintegrates in about 30 s or less by USP <701>; weight ideally ≤500 mg | Absorption site | Levetiracetam ODT |
Start with the pharmacopoeia, not the brochure
The European Pharmacopoeia's Oromucosal preparations monograph (1807) recognizes two film types: orodispersible films, single- or multilayer sheets that disperse rapidly in the mouth, and mucoadhesive buccal films, which stick to the cheek lining and release over time. That split is the one a specification needs. A 2023 review in Pharmaceutics tabulates the compendial expectation for an ODF as disintegration in not more than 60 seconds and a film under 200 mg. Everything else in the vocabulary is a route or a slogan.
ODF versus OTF
ODF is the compendial name. OTF, oral thin film, is trade shorthand covering dispersing films, buccal films and anything cast thin. FDA's drug-listing vocabulary uses FILM, FILM, SOLUBLE and FILM, EXTENDED RELEASE; a supplement strip never carries those terms, because it is a supplement in film form with a Supplement Facts panel. Our practice: ODF in the specification and batch record, OTF only where buyers search for it.
Sublingual and buccal are routes, and routes need evidence
The prescription films show what the placement word carries. Buprenorphine/naloxone sublingual film is held under the tongue until dissolved, typically 5–10 minutes, and the label also allows buccal placement. Buprenorphine buccal film adheres to the cheek and dissolves over about 30 minutes, in seven strengths from 75 to 900 micrograms. Both come with pharmacokinetic studies.
Placement alone proves little. Desmopressin, a small peptide, is sold as a sublingual lyophilisate with a labelled mean bioavailability of 0.25 percent. Rule for a supplement strip: if you cannot measure what crosses the mucosa, say "dissolves in the mouth" and keep sublingual off the front panel.
Fast-dissolving, melt-in-mouth, oral strip
Search terms, and useful ones. Breath strips, the product most people picture, are pullulan films with menthol and flavor, sold as oral care. None of these words fixes a dissolve time, a placement or an evidence standard. Our development targets put numbers on them: 22 × 32 mm, about 50–150 μm dry, roughly 100–300 mg finished, 30–60 seconds to dissolve. For scale, the 12 mg/3 mg buprenorphine/naloxone film measures 22.0 × 19.2 mm.
Why films are not small tablets
FDA's ODT guidance asks for disintegration in about 30 seconds or less and a tablet weight of no more than 500 mg. A film weighs a fraction of that, which is why ODF reviews put the practical active load near 50 mg and the ceiling near 100 mg even for bilayer designs. A 500 mg serving has already chosen its format.
Worked example: writing the term into a specification
A brand asks for a "sublingual B12 strip." The specification we would write: orodispersible film, 22 × 32 mm, target dissolve 30–60 seconds, placed on or under the tongue at the user's preference, no absorption claim. Front panel: "dissolves in the mouth." Same product; the language now matches the evidence, and the disintegration test in the release specification is the one the term implies.
The questions that matter more than the label
Where is it placed, what must it do there, how does the active behave in a wet film, which test proves the dissolve claim, how does the sachet protect it, and which regulatory pathway applies. Those answers define the product. The acronym is a search term.
Common questions
No. Both disintegrate in the mouth, but an ODT is a compressed tablet that FDA expects to disintegrate in about 30 seconds and weigh up to 500 mg. A film is cast, weighs far less, and carries far less active.
It can be placed under the tongue, and the label can say so. Implying that the placement changes absorption is a claim, and it needs data the strip probably does not have.
No. It is a format description used for drugs, supplements and oral-care products alike. The regulatory class comes from the ingredient and the claims, not the film.
Primary sources
- Pharmaceutics (2023) — Orodispersible Films: Current Innovations and Emerging Trends (Ph. Eur. definition, quality attributes)
- FDA — Structured Product Labeling dosage form vocabulary
- FDA — Guidance for Industry: Orally Disintegrating Tablets (2008)
- FDA — Suboxone (buprenorphine and naloxone) sublingual film prescribing information
- FDA — Belbuca (buprenorphine) buccal film prescribing information
- DailyMed — Sympazan (clobazam) oral film label
- FDA — Zuplenz (ondansetron) oral soluble film prescribing information
- emc — DDAVP Melt 60 mcg oral lyophilisate, Summary of Product Characteristics
- CVS — Listerine PocketPaks breath strips ingredient list
Formula feasibility, packaging, testing, claims, timing, and final quantities depend on the exact product. Use this guide to prepare better questions, then confirm the production plan for your project.